Leukoreduction in the setting of open heart surgery: a prospective cohort-controlled study - PubMed (original) (raw)
Clinical Trial
Leukoreduction in the setting of open heart surgery: a prospective cohort-controlled study
Mark K Fung et al. Transfusion. 2004 Jan.
Abstract
Background: Proven clinical benefits of leukoreduced blood components include reduced febrile nonhemolytic transfusion reactions, alloimmunization against HLA antigens, and CMV transmission. Immunomodulatory effects of leukoreduction have also been postulated to play a significant role in the clinical outcome of open heart surgery.
Study design and methods: A prospective case control study was implemented in which all patients admitted over a 1-year period for open heart surgery at a single hospital were given leukoreduced blood products. Clinical outcomes were prospectively measured and compared to a historical cohort of patients from the previous year when leukoreduced blood products were not routinely used.
Results: A significant improvement in the mean postoperative length of stay was seen in the study group (N = 645) versus control group (N = 501; 10.1 vs. 9.5 days; p = 0.005). No significant changes were seen in the rate of mediastinitis, operative mortality, or stay in the intensive care unit. There was no difference in the postoperative length of stay among study patients who did not receive transfusion (N = 308) versus control patients who did not receive transfusion (N = 296; 6.2 vs. 6.4 days; p = 0.104).
Conclusions: The use of leukoreduced blood was associated with a decrease in the postoperative length of stay in the setting of open heart surgery. The mechanisms through which these changes in clinical outcomes are generated remain unknown.
Similar articles
- Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
Kekre N, Tokessy M, Mallick R, McDiarmid S, Huebsch L, Bredeson C, Allan D, Tay J, Tinmouth A, Sheppard D. Kekre N, et al. Biol Blood Marrow Transplant. 2013 Dec;19(12):1719-24. doi: 10.1016/j.bbmt.2013.09.013. Epub 2013 Oct 5. Biol Blood Marrow Transplant. 2013. PMID: 24099958 - Clinical effects of reverting from leukoreduced to nonleukoreduced blood in cardiac surgery.
Fung MK, Moore K, Ridenour M, Mook W, Triulzi DJ. Fung MK, et al. Transfusion. 2006 Mar;46(3):386-91. doi: 10.1111/j.1537-2995.2006.00733.x. Transfusion. 2006. PMID: 16533280 - Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions.
Hébert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, Heddle N, Germain M, Goldman M, Toye B, Schweitzer I, vanWalraven C, Devine D, Sher GD; Leukoreduction Study Investigators. Hébert PC, et al. JAMA. 2003 Apr 16;289(15):1941-9. doi: 10.1001/jama.289.15.1941. JAMA. 2003. PMID: 12697796 - Leukoreduction of blood components.
Dzik WH. Dzik WH. Curr Opin Hematol. 2002 Nov;9(6):521-6. doi: 10.1097/00062752-200211000-00010. Curr Opin Hematol. 2002. PMID: 12394176 Review. - Sutureless Aortic Valve Replacement for Treatment of Severe Aortic Stenosis: A Single Technology Assessment of Perceval Sutureless Aortic Valve [Internet].
Desser AS, Arentz-Hansen H, Fagerlund BF, Harboe I, Lauvrak V. Desser AS, et al. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Aug 25. Report from the Norwegian Institute of Public Health No. 2017-01. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Aug 25. Report from the Norwegian Institute of Public Health No. 2017-01. PMID: 29553663 Free Books & Documents. Review.
Cited by
- Transfusion immunomodulation--the case for leukoreduced and (perhaps) washed transfusions.
Lannan KL, Sahler J, Spinelli SL, Phipps RP, Blumberg N. Lannan KL, et al. Blood Cells Mol Dis. 2013 Jan;50(1):61-8. doi: 10.1016/j.bcmd.2012.08.009. Epub 2012 Sep 13. Blood Cells Mol Dis. 2013. PMID: 22981700 Free PMC article. Review. - Prestorage leukoreduction ameliorates the effects of aging on banked blood.
Phelan HA, Gonzalez RP, Patel HD, Caudill JB, Traylor RK, Yancey LR, Sperry JL, Friese RS, Nakonezny PA. Phelan HA, et al. J Trauma. 2010 Aug;69(2):330-7. doi: 10.1097/TA.0b013e3181e0b253. J Trauma. 2010. PMID: 20699741 Free PMC article. - Balance Between the Proinflammatory and Anti-Inflammatory Immune Responses with Blood Transfusion in Sepsis.
Rice TC, Pugh AM, Caldwell CC, Schneider BSP. Rice TC, et al. Crit Care Nurs Clin North Am. 2017 Sep;29(3):331-340. doi: 10.1016/j.cnc.2017.04.003. Epub 2017 Jun 23. Crit Care Nurs Clin North Am. 2017. PMID: 28778292 Free PMC article. Review. - Use of leukoreduced blood does not reduce infection, organ failure, or mortality following trauma.
Englehart MS, Cho SD, Morris MS, Gee AC, Riha G, Underwood SJ, Differding JA, Luem ND, Wiesberg TT, Boshkov LK, Schreiber MA. Englehart MS, et al. World J Surg. 2009 Aug;33(8):1626-32. doi: 10.1007/s00268-009-0076-5. World J Surg. 2009. PMID: 19452207 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials